Methanol Extracts from *Manilkara zapota* with Moderate Antibacterial Activity Displayed Strong Antibiotic-Modulating Effects against Multidrug-Resistant Phenotypes

*Franklin C. M. Ngongang1,2, Aimé G. Fankam1, Armelle T. Mbaveng1\*, Brice E. N. Wamba1, Paul Nayim1, Veronique P. Beng2, and Victor Kuete1\*\**

*1Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon*

*2Department of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon*

***Author’s addresses***

*Franklin C. M. Ngongang,:* *franklinngongang@yahoo.fr*

*Aimé G. Fankam, agfankam@yahoo.fr*

*Armelle T. Mbaveng: armbatsa@yahoo.fr*

*Paul Nayim,* *nayimpaul@yahoo.fr*

*Brice E. N. Wamba,* *wambaelvis@yahoo.fr*

*Veronique P. Beng: v.penlap@yahoo.fr*

*Victor Kuete:* *kuetevictor@yahoo.fr*

***Corresponding authors:***

*Tel.: +237 675468927; E-mail address: armbatsa@yahoo.fr (Prof. Dr A.T. Mbaveng)*

*Tel.: +237 677355927; E-mail address: kuetevictor@yahoo.fr (Prof. Dr Victor Kuete)*

**Table S1.** Gram-negative bacteria and their features

|  |  |  |
| --- | --- | --- |
| **Strains** | **Features** | **References** |
| ***Escherichia coli*** |  |  |
| ATTC 8739 andATCC10536 | Reference strain  |  |
| AG 100 | Wild-type *E. coli* K-12 expressing *Acr AB* efflux pumps | [1] |
| AG 100ATet | ΔacrAB mutant AG 100A Tetr | [1] |
| AG 102 | AG 100 expressing *Acr AB* pumps | [2] |
| W 3110 | Wild-type E.*coli* K-12 | [3] |
| MC4100 | Wild-type E. coli K-12, KANR expressing *ABC* pump  | [3] |
| ***Enterobacter aerogenes*** |  |  |
| ATCC 13048 | Reference strain |  |
| EA3 | Clinical MDR isolate CHLR, NORR,MOXR, CFTR, ATMR, FEPR | [4] |
| EA 27 | Clinical MDR isolate exhibitingenergy-dependent norfloxacin andchloramphenicol efflux with KANR andAMPR and NALR and STRR and TETR | [5, 6] |
| EA 289 | KAN sensitive derivative of EA27 | [4] |
| EA294 | EA289 expressing *AcrA* pump having KANr | [4, 7] |
| EA 298 | EA 289 tolC:KANR | [4, 7] |
| ***Klebsiella pneumoniae*** |  |  |
| ATCC11296 | Reference strain  |  |
| K 24 | Clinical MDR isolate *AcrAB-Tolc*  | Clinical laboratory collection of UMR-MD1, University of Marseille, France |
| Kp 55 | Clinical MDR isolate, TETR, AMPR, ATMR, and CEFR | [8] |
| Kp 63 | Clinical MDR isolate, TETR, CHLR, AMPR, and ATMR | [8] |
| ***E. Cloacae*** |  |  |
| ECCI69 | Clinical isolates  | Laboratory collection of UNR-MD1, University of Marseille, France |
| ***Providencia stuartii*** |  |  |
| NEA 16 | Clinical MDR isolate, *AcrAB-TolC* | [9] |
| PS2636 | Clinical MDR isolate, *AcrAB-TolC* |
| ***Pseudomonas aeruginosa*** |  |  |
| PA 01 | Reference strain |  |
| PA 124 | Clinical MDR isolate | [10] |

aAMPR, ATMR, CEFR, CFTR, CHLR,CIPR, ERMR, FEPR, FLXR, IM/CSR, KANR, MOXR, OFXR, STRR, TETR, Resistancetoampicillin, aztreonam, cephalothin, cefadroxil, chloramphenicol, Ciprofloxacin, Erythromycin, cefepime,Flomoxef, Imipenem/ Cilastatinsodium, kanamycin, moxalactam, streptomycin, andtetracycline; MDR : Multidrugresistant.

 **Table S1.** *Staphylococcus aureus* strains and features.

|  |  |  |
| --- | --- | --- |
| **Bacteria** | **Features** | **References** |
| *S. aureus MSSA1* | Clinical isolate : Met susceptible ; Nis**r**, Chl**r** |  [11, 12]  |
| *S. aureus MRSA3* | Clinical isolate : Ofxa**r**, Kan**r**, Tet**r**, Ermr |  [12]  |
| *S. aureus MRSA4* | Clinical isolate : Ofxa**r**, Kan**r**, Cyp**r,** Chl**r**, Gen**r,** Nis**r,** Amp**r** |  [11, 12]  |
| *S. aureus MRSA6* | Clinical isolate : Ofxa**r**, Flx**r**, Kan**r**, Tet**r**, Cyp**r**, IM/Cs**r,** Chl**r**, Gen**r,** Nis**r,** Amp**r** | [11, 12]  |
| *S. aureus MRSA8* | Clinical isolate : Ofxa**r**, Flx**r**, Kan**r**, Erm**r**, Cyp**r**, Im/Cs**r,** Chl**r**, Gen**r,** Nis**r,** Amp**r** | [11, 12]  |
| *S. aureus MRSA9* | Clinical isolate : Ofxa**r**, Flx**r**, Tet**r**, Erm**r**, Cyp**r**, Im/Cs**r,** Chl**r**, Gen**r,** Nis**r,** Amp**r** | [11, 12]  |
| *S. aureus MRSA11* | Clinical isolate : Ofxa**r**, Kan**r**, Erm**r**, Cyp**r**, Im/Cs**r,** Chl**r**, Nis**r,** Amp**r** |  [11, 12]  |
| *S. aureus MRSA12* | Clinical isolate : Ofxa**r**, Flx**r**, Kan**r**, Erm**r**, Im/Cs**r,** Chl**r**, Gen**r,** Nis**r,** Amp**r** | [11, 12]  |
| *ATCC 25923* | Reference strain | / |
| *SA01* | Clinical isolate : Erm**r,** Amp**r** | [13, 14] |
| *SA07* | Clinical isolate : Erm**r,** Dox**r** | [13, 14] |
| *SA18* | Clinical isolate : Amp**r,** Dox**r,** Vm**r** | [13, 14] |
| *SA23* | Clinical isolate : Imi**r**, Aug**r** | [13, 14] |
| *SA36* | Clinical isolate : Dox**r,** Vm**r** | [13, 14] |
| *SA56* | Clinical isolate : Amp**r,** Dox**r** | [13, 14] |
| *SA68* | Clinical isolate : Amp**r,** Vm**r** | [13, 14] |
| *SA88* | Clinical isolate : Erm**r,** Vm**r** | [13, 14] |
| *SA114* | Clinical isolate : Amp**r,** Dox**r** | [13, 14] |
| *SA126* | Clinical isolate : Amp**r,** Dox**r** | [13, 14] |
| *SA127* | Clinical isolate : Amp**r,** Dox**r** | [13, 14] |

Chl**r**, Cyp**r**, Erm**r**, Flx**r**, Im/Cs**r**, Kan**r**, Met**r**, Ofxa**r**, Tet**r**, Vm**r**, Amp**r**, Dox**r**, Aug**r**, Gen**r** and Nis**r** résistance to : chloramphenicol; Cyprofloxacin; Erythromycin; Flomoxef; Imipenem/Cilastatin sodium; Kanamycin; Méthicillin; Ofloxacin; Tetracycline; Vancomycin ; Ampicillin ; Doxycycline ; Augmentin ; Gentamicin ; Nisin respectively, *SA : Staphycoccus aureus.*

**References.**

1. Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AA, Molnar J, Amaral L. 2005. Inducement and reversal of tetracycline resistance in *Escherichia coli* K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother*, 49 (8):3578–82.
2. Elkins CA, Mullis LB. 2007. Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of *Escherichia coli*. *Antimicrob Agents Chemother*, 51(3):923–9.
3. Baglioni P, Bini L, Liberatori S, Pallini V, Marri L. 2003. Proteome analysis of *Escherichia coli* W3110 expressing an heterologous sigma factor. *Proteomics*, 3(6): 1060–5.
4. Ghisalberti D. Masi M, Pages JM, Chevalier J. 2005. Chloramphenicol and expression of multidrug efflux pump in *Enterobacter aerogenes*. *Biochem Biophys Res Commun*, 328(4):1113–18.
5. Mallea M, Mahamoud A, Chevalier J, Alibert-Franco S, Brouant P, Barbe J, Pagès J-M. 2003. Alkylamino- quinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates. *Biochem J*, 376(3):801–5.
6. Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C, Pagès J-M. 1998. Porin alteration and active efflux: two *in vivo* drug resistance strategies used by *Enterobacter aerogenes*. *Microbiology*, 144(11):3003–9.
7. Pradel E, Pages J-M. 2002.The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen *Enterobacter aerogenes*. *Antimicrob Agents Chemother*, 46(8):2640–3.
8. Chevalier J, Pages J-M, Eyraud A, Mallea M. 2000. Membrane permeability modifications are involved in antibiotic resistance in *Klebsiella pneumonia*. *Biochem Biophys Res Commun*, 274(2): 496–9.
9. Tran Q-T, Mahendra KR, Hajjar A, Ceccarelli M, Davin-Regli A, Winterhalter M, Weingart H, Pagès J-M. 2010. Implication of porins in ß-lactam resistance of *Providencia stuartii*. *J Biol Chem*, 285: 32273-81.
10. Lorenzi V, Muselli A, Bernardini AF, Berti L, Pages JM, Amaral L, Bolla JM. 2009. Geraniol restores antibiotic activities against multidrug-resistant isolates from Gram-negative species. *Antimicrob Agents Chemother*, 53: 2209–11.
11. Dzoyem JP, Hamamoto H, Ngameni B, Ngadjui BT, Sekimizu K.2013. Antimicrobial action mechanism of flavonoids from *Dorstenia* species. *Drug Discov Ther,* 7(2):66-72.
12. Paudel A, Hamamoto H, Kobayashi Y, Yokoshima S, Fukuyama T, Sekimizu K. 2012. Identification of novel deoxyribofuranosyl indole antimicrobial agents. *J Antibiot (Tokyo),* 65(2):53-7.
13. Badawe G, Fankam AG, Nayim P, Wamba BEN, Mbaveng AT, Kuete V. 2018. Anti-staphylococcal activity and antibiotic-modulating effect of *Olax subscorpioidea, Piper guineense, Scorodophloeus zenkeri, Fagara leprieurii*, and *Monodora myristica* against resistant phenotypes. *Invest Med Chem Pharmacol*, 1(2):17.
14. Manekeng HT, Mbaveng AT, Nguenang GS, Seukep JA, Wamba BEN, Nayim P, Yinkfu NR, Kuete V. 2018. Anti-staphylococcal and antibiotic-potentiating activities of seven Cameroonian edible plants against resistant phenotypes. *Invest Med Chem Pharmacol*, 1(1):7.